Lipohep

Heparin Sodium, the active ingredient in Lipohep, is an anticoagulant presented as a standard concentration solution for cutaneous use. It prevents clot formation in patients at risk of venous thromboembolism, deep vein thrombosis and pulmonary embolism. GNH USA supplies Lipohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lipohep is an anticoagulant that acts on the coagulation cascade to reduce thrombotic events. - Venous thromboembolism: prevents new clot formation and recurrence in affected patients. - Deep vein thrombosis prophylaxis: lowers the incidence of DVT in surgical or immobilised individuals. - Pulmonary embolism prevention: inhibits clot propagation to the pulmonary arteries, reducing embolic risk.

Lipohep may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Injection site bruising or hematoma. - Minor bleeding such as nosebleeds or gum bleeding. - Local pain or erythema at the injection site. - Transient thrombocytopenia. - Urticaria or mild skin rash.

Serious or Rare Side Effects: - Heparin‑induced thrombocytopenia (HIT), a potentially life‑threatening immune reaction. - Major hemorrhage, including intracranial or gastrointestinal bleeding. - Spinal or epidural hematoma when administered near the spine. - Anaphylactic shock or severe allergic reaction. - Osteopenia with prolonged high‑dose therapy.

Before initiating Lipohep therapy, clinicians should assess individual risk factors and monitor patients closely. - Monitor coagulation parameters: check aPTT or anti‑Xa levels as directed. - Assess bleeding risk: evaluate history of hemorrhage or active bleeding. - Review renal and hepatic function: adjust therapy if organ impairment is present. - Avoid concurrent anticoagulants unless medically justified: limit use with warfarin, DOACs, or thrombolytics. - Store at room temperature: keep in original container, protect from moisture and light.

Heparin Sodium can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increased bleeding risk. - Administration with thrombolytic agents (e.g., alteplase): heightened hemorrhagic complications. - Combination with non‑steroidal anti‑inflammatory drugs (NSAIDs): potentiates bleeding.

Moderate Interactions (Monitor Closely): - Co‑administration with antiplatelet agents (e.g., aspirin, clopidogrel): monitor for additive bleeding. - Use with systemic corticosteroids: may increase gastrointestinal bleeding risk. - Interaction with ACE inhibitors: observe for rare bleeding events.